We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

17 hedge funds and large institutions have $382K invested in Phio Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

55% more funds holding

Funds holding: 11 → 17 (+6)

0.09% more ownership

Funds ownership: 3.29% → 3.38% (+0.09%)

18% less capital invested

Capital invested by funds: $467K → $382K (-$85.1K)

Holders
17
Holders Change
+6
Holders Change %
+54.55%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
5
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$55.6K
2
Northern Trust
Northern Trust
Illinois
+$38K
3
DS
DRW Securities
Illinois
+$36.2K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$32.1K
5
Two Sigma Investments
Two Sigma Investments
New York
+$23.2K

Top Sellers

Rank Fund Capital Flow
1
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$1.02K
2
TRCT
Tower Research Capital (TRC)
New York
-$1.01K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
1
Geode Capital Management
Massachusetts
$97.3K +$55.6K +34,732 +60%
Vanguard Group
2
Vanguard Group
Pennsylvania
$92K – – –
Cetera Investment Advisers
3
Cetera Investment Advisers
Illinois
$44.6K +$14.4K +9,000 +27%
Northern Trust
4
Northern Trust
Illinois
$24.9K +$38K +23,758 New
DS
5
DRW Securities
Illinois
$23.8K +$36.2K +22,636 New
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$21.1K +$32.1K +20,091 New
Two Sigma Investments
7
Two Sigma Investments
New York
$15.2K +$23.2K +14,494 New
SG
8
StoneX Group
New York
$12.4K +$18.9K +11,828 New
RSWM
9
Robertson Stephens Wealth Management
California
$11.3K +$17.3K +10,800 New
VF
10
Virtu Financial
New York
$11K +$16.3K +10,214 New
CAPTRUST Financial Advisors
11
CAPTRUST Financial Advisors
North Carolina
$10.5K +$16K +10,000 New
UBS Group
12
UBS Group
Switzerland
$9.02K +$13.7K +8,581 +66,008%
Morgan Stanley
13
Morgan Stanley
New York
$6.3K – – –
Bank of America
14
Bank of America
North Carolina
$1.48K +$21 +13 +0.9%
SS
15
SBI Securities
Japan
$1.19K +$54 +34 +3%
AssetMark Inc
16
AssetMark Inc
California
$116 – – –
AWM
17
Activest Wealth Management
Florida
$9 – – –
BNP Paribas Financial Markets
18
BNP Paribas Financial Markets
France
– -$1.02K -413 Closed
TRCT
19
Tower Research Capital (TRC)
New York
– -$1.01K -406 Closed

PHIO Hedge Fund Activity: Q4 2025 in Review

17 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2025, worth a combined $382K — down 18% from $467K a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new PHIO positions and 2 closed out — a net gain of 6 holders — while 5 added to existing stakes and 0 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $55.6K. The largest seller was BNP Paribas Financial Markets, exiting entirely with an estimated $1.02K sold.

  • 17 institutional investors held Phio Pharmaceuticals (PHIO) as of Q4 2025, up from 11 in Q3 2025.
  • Funds reported $382K of Phio Pharmaceuticals stock for Q4 2025, down 18% quarter-over-quarter.
  • 8 funds opened new Phio Pharmaceuticals positions in Q4 2025 and 2 closed out, a net change of +6 holders.
  • The largest Phio Pharmaceuticals buyer in Q4 2025 was Geode Capital Management, an estimated $55.6K added.
  • The largest Phio Pharmaceuticals seller in Q4 2025 was BNP Paribas Financial Markets, an estimated $1.02K sold.

Based on aggregated 13F filings for Q4 2025.